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Messina, Naples, and Mercogliano, ItalyObjectives The aim of this prospective registry was to evaluate the safety and efﬁcacy at 2-year
follow-up of the use of drug-eluting balloons (DEBs) for the treatment of superﬁcial femoral artery
(SFA) in-stent restenosis (ISR).
Background The use of DEBs for the treatment of SFA ISR is associated with a satisfactory primary
patency rate at 1 year, but no data are available for longer follow-up. Unfortunately, when DEBs were
used to treat SFA de novo lesions, the occurrence of restenosis increased by 50% between the ﬁrst and
the second years of follow-up.
Methods From December 2009 to December 2010, 39 consecutive patients underwent percutaneous
transluminal angioplasty of SFA ISR at our institution (Clinica Montevergine, Mercogliano, Italy). All
patients underwent conventional SFA percutaneous transluminal angioplasty and ﬁnal post-dilation
with paclitaxel-eluting balloons (IN.PACT, Medtronic Inc., Minneapolis, Minnesota). Patients were
evaluated for up to 24 months.
Results During follow-up, 1 patient died of heart failure and another of sudden death, for a 2-years
rate of cardiovascular mortality rate of 5.12 %. The primary patency rate at 2 years was 70.3% (11 of 37
patients experienced restenosis recurrence at 2-year follow-up). The treatment of complex ISR lesions
(classes II and III) was associated with an increased rate of recurrent restenosis compared with class I
(33.3 % and 36.3 % vs. 12.5%; p ¼ 0.05).
Conclusions The data suggest that adjunctive use of DEBs for the treatment of SFA ISR is a safe and
effective therapeutic strategy up to 2 years of follow-up. (J Am Coll Cardiol Intv 2014;7:411–5)ª 2014
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412The use of self-expanding nitinol stents has improved the
patency rate of percutaneous transluminal angioplasty (PTA)
of the superﬁcial femoral artery (SFA). Unfortunately, the
occurrence of SFA in-stent restenosis (ISR) has been reported
to occur within 1 year in at least one-fourth of the patients (1).
The use of drug-eluting balloons (DEBs) for the treat-
ment of SFA ISR has shown promising results in terms of
clinical beneﬁt and primary patency over 1 year (2). When
DEBs were used to treat SFA lesions, the occurrence of
restenosis increased by 50% between the ﬁrst and the second
years of follow-up (3). No data are available on the SFA ISR
long-term recurrence and late thrombosis occurrence.
The aim of this registry was to provide 2-year follow-up
data on the use of DEBs for the treatment of SFA ISR.
Methods
Study population. From December 2009 to December
2010, 39 patients underwent PTA for the treatment of SFA
ISR at our institution (of a total of 308 SFA interventions).Abbreviations
and Acronyms
DEB = drug-eluting balloon
ISR = in-stent restenosis
PTA = percutaneous
transluminal angioplasty
PVR = proximal velocity ratio
SFA = superﬁcial femoral
artery
TLR = target lesion
revascularizationPatients were treated in the
standard manner of our practice
and included in a prospective
registry. The follow-up protocol
was approved by the hospital
institutional review board.
Concomitant therapy. All pa-
tients received aspirin (75 to 160
mg/day) and should have been
on ticlopidine (250 mg twice
daily) for at least 7 days. Alter-
natively, patients received a clo-
pidogrel pre-load (300 mg) 24 hbefore the procedure. After the procedure, thienopyridines
were continued for 30 days, whereas aspirin continued for
life. For anticoagulation, 70 to 100 IU/kg of unfractionated
heparin was administered, with the intention to achieve an
activated clotting time of >250 s.
PTA technique. All procedures were performed percutane-
ously as previously reported (2). All patients underwent
standard balloon angioplasty for at least 60 s, sizing was
0.8:1 to the reference vessel diameter. Laser-mediated lesion
debulking was used to substitute balloon pre-dilation at
the operator’s discretion. A ﬁnal post-dilation, at least 180 s,
was performed with DEBs (IN.PACT, Medtronic Inc.,
Minneapolis, Minnesota) and sizing was 1:1 to the reference
vessel diameter. The IN.PACT balloon has a surface-
speciﬁc matrix coating consisting of paclitaxel combined
with an hydrophilic spacer (Freepac, Medtronic, Inc.) (4).
Nitinol stent implantation was allowed for bail-out stenting
(residual stenosis >30% or ﬂow-limiting dissections).
Patients follow-up. Patients were evaluated through
hospital discharge, at 30 days, and at 3, 6, 12, 15, 18, 21,
and 24 months post-procedure. Clinical follow-up wasperformed by clinical examinations and duplex ultraso-
nography scans. Repeat angiography was performed when
proximal ﬂow velocity ratio (PVR) was between 2.4 and
5.0 (intermediate restenosis), and the patient had clinical
symptoms or >5.0 PVR (severe restenosis) regardless of
clinical symptoms and in case of stent occlusion (5).
Classiﬁcation of ISR. The ISR lesions were classiﬁed by a
visual estimate on angiography: class I, the focal (<50 mm in
length) ISR group included lesions located at the stent body,
the stent edge, or a combination of these sites; class II, the
diffuse (>50 mm in length) ISR group, included not only
stent body lesions, but also stent edge lesions; and class III is
the totally occluded ISR group (5).
Deﬁnitions. Technical success was deﬁned as the ability to
successfully perform PTA and DEB post-dilation with a
residual stenosis <30%. Procedural success was deﬁned as
technical success without the occurrence of any in-hospital
major adverse cardiac and cerebrovascular events. The pri-
mary endpoint was primary patency deﬁned as a PVR <2.4
documented by duplex ultrasound at 12 months without
target lesion revascularization (TLR). Secondary endpoints
included freedom from TLR at 2 years, and secondary
patency at 2 years documented by duplex ultrasound
(patency deﬁned as a PVR <2.4). Stent fractures were
classiﬁed as minor, moderate, or severe (6).
The below-the-knee artery was considered patent if free
of obstructive lesions demonstrating angiographic stenosis
>70%.
Statistics. Statistical analyses were performed using SPSS
version 16.0 (SPSS, Inc., Chicago, Illinois). Variables were
expressed as absolute numbers and percentage or mean 
SD. Comparisons were made using the t test for unpaired
samples, the chi-square test, or the Mann-Whitney U test,
as appropriate. Additionally, the Kaplan-Meier estimate was
used for presentation of primary patency and the freedom
from TLR through 24 months.
An exploratory analysis was undertaken to identify pre-
dictors of restenosis. The methodology used was a 2-step
approach. First, possible predictors (stent length, stent
diameter, stent fracture, stent located in the distal SFA, ISR
class, age, sex, smoking history, hypertension, diabetes
mellitus, hypercholesterolemia, number of below-the-knee
patent vessels, laser use, and bail-out stenting) were selected
from the baseline variables and evaluated by analysis of
variance for continuous variables and chi-square test versus
restenosis for categorical variables. The second step was to
enter the variables in a binary logistic linear model. Variables
with p < 0.05 were considered signiﬁcant predictors of
restenosis.
Results
Patients’ clinical characteristics and procedural features
were previously reported (2). Technical and procedural
Figure 2. Kaplan-Meier Curve Representing Freedom From TLR
Curve shows freedom from target lesion revascularization (TLR) up to 2 years
after drug-eluting balloon–mediated percutaneous transluminal angioplasty
of superﬁcial femoral artery in-stent restenosis. Dotted lines indicate 95%
conﬁdence interval.
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413success was achieved in all 39 patients (100%). No proce-
dure-related adverse events occurred. Summarized proce-
dural characteristics were previously reported (2). All
restenosis classes were represented: 20.5% (n ¼ 8) were
class I, 48.7% (n ¼ 19) were class II, and 30.8 % (n ¼ 12)
were class III.
No major adverse cardiac and cerebrovascular events
occurred in hospital. During the 2-years follow-up, 1 patient
died due to heart failure after 3 months, and 1 patient died
due to sudden death at 18 months, resulting in 2.56% 1-year
and 5.12% 2-year rates of all-cause and cardiovascular
mortality.
The primary endpoint, primary patency at 2 years, was
obtained in 70.3% (26 of 37 patients) completing the 2-year
follow-up (Fig. 1); consequently, a total of 11 patients
experienced recurrent ISR during the follow-up. Freedom
from TLR rate at 2 years was 78.4% (Fig. 2).
In 1 patient, the 3-month follow-up duplex scan showed
a signiﬁcant class I restenosis, which was treated by PTA
and DEB.
At the 6-month follow-up, recurrent restenosis was
treated with DEB in a patient (class I) and with an endo-
vascular graft in another (class II). One patient underwent an
in-stent recanalization with DEB for a class III ISR at 14
months. At 16 months, 1 patient underwent a femorotibial
bypass graft after an unsuccessful PTA of a class III ISR.
After 17 months, a duplex scan showed a signiﬁcant class II
ISR in 1 patient; despite the presence of symptoms; patient
refused further treatment.
At 18 months, 1 patient with class II ISR was treated
by implantation of an endovascular graft. A second patient,
in whom class III ISR occurred after omolateral common
femoral artery (CFA) clamping due to emergency surgery forFigure 1. Kaplan-Meier Curve Representing Primary Patency
Curve shows primary patency up to 2 years after drug-eluting balloon–
mediated percutaneous transluminal angioplasty of superﬁcial femoral artery
in-stent restenosis. Dotted lines indicate 95% conﬁdence interval.a ruptured abdominal aortic aneurysm, was placed on
medical therapy.
At 20 months, signiﬁcant target lesion restenosis occurred
in 2 patients, 1 of whom underwent PTA with laser-mediated
debulking and endovascular graft implantation for a class III
ISR. The second patient, with class III ISR, was treated by
medical therapy because of her advanced age and comor-
bidity. One patient had class II ISR at 23 months and was
treated by a new stent implantation with successive DEBs.
At 2 years, duplex assessment demonstrated an 87% rate
of secondary patency; Rutherford class was 0.6  0.7
(baseline, 2.9  0.7; p < 0.05), and the ankle-brachial index
was 0.94  0.09 (baseline, 0.77  0.09; p < 0.05).
Of the 37 patients who completed the 2-year follow-up, a
second PTA was performed in only 5 patients. Two patients
underwent surgical revascularization, and 2 patients were
treated medically.
The treatment of more complex ISR lesions (classes II
and III) with DEBs was associated with an increased rate
of recurrent restenosis compared with class I (33.3% and
36.3% vs. 12.5%; p ¼ 0.05) (Fig. 3).Discussion
This study demonstrates that the use of DEBs is associated
with low rates of recurrences at 2 years. The treatment of
ISR in the femoropopliteal artery is 1 of the remaining
challenges of endovascular therapy because different treat-
ment modalities, such as PTA and cutting balloon angio-
plasty, have failed to provide durable results (7). To avoid
Figure 3. Restenosis Recurrence According to Baseline ISR Class
Bar graph representing superﬁcial femoral artery in-stent restenosis (SFA ISR)
recurrence at 2 years in patients treated with drug-eluting balloons for SFA ISR
according to ISR class at baseline (p ¼ 0.05).
Table 1. Patterns of In-Stent Restenosis at Baseline and at Recurrence
Class Baseline Recurrence p Value
I 20.5 (8) 18.2 (2) NS
II 48.7 (19) 36.4 (4) NS
III 30.8 (12) 45.4 (5) NS
Values are % (n).
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414bypass surgery, alternative endovascular approaches are
needed to achieve better and more durable results.
ISR is determined by neointimal hyperplasia of smooth
muscle cells; to reduce neointima formation, it is necessary
to arrest smooth muscle cell proliferation and migration (8).
Local arterial wall delivery of paclitaxel, a drug that impairs
normal microtubule and cytoskeleton arrangement, may
prevent neointimal hyperplasia by inhibiting smooth muscle
cell migration and proliferation (9). This approach, thanks
to the use of drug-eluting technologies, is being investigated
as a potential treatment of SFA ISR.
Regarding the potential role of DEBs in the treatment
of femoropopliteal ISR, we previously reported a 1-year
primary patency rate of 92.1% (1). Similar data have been
reported in diabetic patients. In the DEBATE trial, (Drug-
Eluting Balloon in peripherAl inTErvention) treatment of
ISR with DEBs demonstrated a signiﬁcant reduction in
restenosis recurrence compared with standard balloon an-
gioplasty (10).
More recent data have been published on the role of
drug-eluting stents for the treatment of SFA ISRS. In
Zilver PTX (Cook Medical, Bloomington, Indiana),
treatment of 119 ISR lesions with a paclitaxel-eluting
stent had an estimated primary patency rate of 95.7% at
6 months and 78.8% at 12 months. The placement of a
second stent layer does not appear to adversely affect the
integrity of the Zilver PTX stent as only 1.2% (3 of 257) of
stents used in this study had detectable fractures at 12
months (11).
It has to be considered that the initial experiences with
the use of drug-eluting technologies have failed due to the
occurrence of a “catch-up” phenomenon resulting in com-
parable clinical and angiographic event rates between groups
in the long term (12,13).When DEBs were used to treat SFA lesions, the occur-
rence of restenosis increased by 50% between the ﬁrst and
second years of follow-up. In the present study, the phe-
nomenon was even more evident.
The value of longer follow-up when evaluating drug-
eluting technologies for the treatment of SFA ISRS relies on
the need to understand whether this is a catch-up phe-
nomenon or is the natural history of ISR.
Notably, the Zilver-PTX single-arm trial is the ﬁrst
prospective study to report 2-year results for endovascular
treatment of femoropopliteal ISR lesions. Freedom from
clinically-driven TLR was 60.8% at 2 years. No predictors of
recurrent ISR were identiﬁed.
We report the longest follow-up after DEB-based PTA
for SFA ISR. At 2 years, a 70.3% primary patency rate was
observed. Similar to Zilver PTX data, no predictors of
restenosis were identiﬁed. A higher restenosis recurrence
rate was observed with more complex restenosis patterns
(type II and II). No difference in the class of ISR was
observed between baseline and recurrence (Table 1).
Due to the limited number of patients enrolled in this
study, the information obtained should be considered more
to support the safety and feasibility of the proposed tech-
nique than to assess efﬁcacy. Nevertheless, comparing
the results of our study with those available in the litera-
ture (5), it is evident that the use of DEBs for the treatment
of SFA ISR reduces restenosis recurrence. As of today, the
only reported recurrence rates of SFA-ISR (5) are 49.9%
when a class I lesion is treated, 53.3% for class II, and 84.8%
for class III. Our study reports a robust reduction in recur-
rence rates (12.5% for class I, 38.9% for class II, and 27.3%
for class III) because of the use of DEBs. The treatment of
more complex ISR lesions (classes II and III) with DEBs
was associated with an increased rate of recurrent restenosis
compared with class I. Unfortunately, due to the limited
number of patients enrolled in the study, this did not reach
a full statistical signiﬁcance.
These observations should be considered hypothesis
generating and be conﬁrmed by larger trials or registries.
Study limitations. The major limitation of our study lies
in the absence of a control group. The relevance of these data
in contemporary practice is somewhat increased by the fact
that they could be used to design a randomized trial
comparing the use of drug-eluting technologies for the
treatment of SFA-ISR.
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